Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says

MT Newswires Live03-18

Soleno Therapeutics (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.

Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.

The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.

The firm added that while it expects a seasonal impact to Q1, the current market expectations are "conservative." It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.

Oppenheimer reiterated its outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110.

Price: 33.10, Change: -0.52, Percent Change: -1.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620509902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620509902","market":"nz","top_or_hot":-1,"title":"Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.</p><p>Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.</p><p>The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.</p><p>The firm added that while it expects a seasonal impact to Q1, the current market expectations are \"conservative.\" It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.</p><p>Oppenheimer reiterated its outperform rating on Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> but lowered its price target to $80 from $110.</p><p>Price: 33.10, Change: -0.52, Percent Change: -1.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-18 23:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.</p><p>Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.</p><p>The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.</p><p>The firm added that while it expects a seasonal impact to Q1, the current market expectations are \"conservative.\" It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.</p><p>Oppenheimer reiterated its outperform rating on Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> but lowered its price target to $80 from $110.</p><p>Price: 33.10, Change: -0.52, Percent Change: -1.55</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPY","symbol_name":"奥本海默控股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620509902","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620509902","pubTimestamp":1773847941,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Soleno Therapeutics  is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.The firm added that while it expects a seasonal impact to Q1, the current market expectations are \"conservative.\" It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.Oppenheimer reiterated its outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110.Price: 33.10, Change: -0.52, Percent Change","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OPY":"奥本海默控股","SLNO":"Soleno Therapeutics"},"translate_title":"奥本海默表示，尽管Vykat XR在美国的上市速度较慢，但Soleno Therapeutics的2026年销售预期仍将超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1.5,"SLNO":1.5},"content_text":"Soleno Therapeutics (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.The firm added that while it expects a seasonal impact to Q1, the current market expectations are \"conservative.\" It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.Oppenheimer reiterated its outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110.Price: 33.10, Change: -0.52, Percent Change: -1.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620509902","isCrawlerRequest":true}